328 related articles for article (PubMed ID: 12672070)
41. Effect of immune mechanisms on the pharmacokinetics and organ distribution of cryptococcal polysaccharide.
Lendvai N; Casadevall A; Liang Z; Goldman DL; Mukherjee J; Zuckier L
J Infect Dis; 1998 Jun; 177(6):1647-59. PubMed ID: 9607845
[TBL] [Abstract][Full Text] [Related]
42. Enzyme immunoassay detection of IgM to galactoxylomannan of Cryptococcus neoformans.
Reiss E; Cherniak R; Eby R; Kaufman L
Diagn Immunol; 1984; 2(2):109-15. PubMed ID: 6388977
[TBL] [Abstract][Full Text] [Related]
43. Characterization of Cryptococcus neoformans capsular glucuronoxylomannan polysaccharide with monoclonal antibodies.
Todaro-Luck F; Reiss E; Cherniak R; Kaufman L
Infect Immun; 1989 Dec; 57(12):3882-7. PubMed ID: 2680986
[TBL] [Abstract][Full Text] [Related]
44. A Paracoccidioides brasiliensis glycan shares serologic and functional properties with cryptococcal glucuronoxylomannan.
Albuquerque PC; Cordero RJ; Fonseca FL; Peres da Silva R; Ramos CL; Miranda KR; Casadevall A; Puccia R; Nosanchuk JD; Nimrichter L; Guimaraes AJ; Rodrigues ML
Fungal Genet Biol; 2012 Nov; 49(11):943-54. PubMed ID: 23010152
[TBL] [Abstract][Full Text] [Related]
45. Antifungal activity of a human antiglucuronoxylomannan antibody.
Zhong Z; Pirofski LA
Clin Diagn Lab Immunol; 1998 Jan; 5(1):58-64. PubMed ID: 9455881
[TBL] [Abstract][Full Text] [Related]
46. Glucuronoxylomannan in the Cryptococcus species capsule as a target for Chimeric Antigen Receptor T-cell therapy.
da Silva TA; Hauser PJ; Bandey I; Laskowski T; Wang Q; Najjar AM; Kumaresan PR
Cytotherapy; 2021 Feb; 23(2):119-130. PubMed ID: 33303326
[TBL] [Abstract][Full Text] [Related]
47. Opsonization of Cryptococcus neoformans by human anticryptococcal glucuronoxylomannan antibodies.
Zhong Z; Pirofski LA
Infect Immun; 1996 Sep; 64(9):3446-50. PubMed ID: 8751883
[TBL] [Abstract][Full Text] [Related]
48. Polysaccharides, mimotopes and vaccines for fungal and encapsulated pathogens.
Pirofski LA
Trends Microbiol; 2001 Sep; 9(9):445-51. PubMed ID: 11553457
[TBL] [Abstract][Full Text] [Related]
49. Cryptococcus neoformans glucuronoxylomannan fractions of different molecular masses are functionally distinct.
Albuquerque PC; Fonseca FL; Dutra FF; Bozza MT; Frases S; Casadevall A; Rodrigues ML
Future Microbiol; 2014; 9(2):147-61. PubMed ID: 24571070
[TBL] [Abstract][Full Text] [Related]
50. Chitin-like molecules associate with Cryptococcus neoformans glucuronoxylomannan to form a glycan complex with previously unknown properties.
Ramos CL; Fonseca FL; Rodrigues J; Guimarães AJ; Cinelli LP; Miranda K; Nimrichter L; Casadevall A; Travassos LR; Rodrigues ML
Eukaryot Cell; 2012 Sep; 11(9):1086-94. PubMed ID: 22562469
[TBL] [Abstract][Full Text] [Related]
51. The capsule of cryptococcus neoformans passively inhibits phagocytosis of the yeast by macrophages.
Kozel TR; Gotschlich EC
J Immunol; 1982 Oct; 129(4):1675-80. PubMed ID: 7050244
[TBL] [Abstract][Full Text] [Related]
52. Capsular polysaccharides from Cryptococcus neoformans modulate production of neutrophil extracellular traps (NETs) by human neutrophils.
Rocha JD; Nascimento MT; Decote-Ricardo D; Côrte-Real S; Morrot A; Heise N; Nunes MP; Previato JO; Mendonça-Previato L; DosReis GA; Saraiva EM; Freire-de-Lima CG
Sci Rep; 2015 Jan; 5():8008. PubMed ID: 25620354
[TBL] [Abstract][Full Text] [Related]
53. Spleen deposition of Cryptococcus neoformans capsular glucuronoxylomannan in rodents occurs in red pulp macrophages and not marginal zone macrophages expressing the C-type lectin SIGN-R1.
De Jesus M; Park CG; Su Y; Goldman DL; Steinman RM; Casadevall A
Med Mycol; 2008 Mar; 46(2):153-62. PubMed ID: 18324494
[TBL] [Abstract][Full Text] [Related]
54. The role of the classical and alternate complement pathways in host defenses against Cryptococcus neoformans infection.
Diamond RD; May JE; Kane MA; Frank MM; Bennett JE
J Immunol; 1974 Jun; 112(6):2260-70. PubMed ID: 4596700
[No Abstract] [Full Text] [Related]
55. Peptide epitopes recognized by a human anti-cryptococcal glucuronoxylomannan antibody.
Zhang H; Zhong Z; Pirofski LA
Infect Immun; 1997 Apr; 65(4):1158-64. PubMed ID: 9119446
[TBL] [Abstract][Full Text] [Related]
56. Isolation and purification of antigenic components of Cryptococcus.
Wozniak KL; Levitz SM
Methods Mol Biol; 2009; 470():71-83. PubMed ID: 19089377
[TBL] [Abstract][Full Text] [Related]
57. Fc-dependent and Fc-independent opsonization of Cryptococcus neoformans by anticapsular monoclonal antibodies: importance of epitope specificity.
Netski D; Kozel TR
Infect Immun; 2002 Jun; 70(6):2812-9. PubMed ID: 12010967
[TBL] [Abstract][Full Text] [Related]
58.
Gonçalves DS; Rodriguez de La Noval C; Ferreira MDS; Honorato L; Araújo GRS; Frases S; Pizzini CV; Nosanchuk JD; Cordero RJB; Rodrigues ML; Peralta JM; Nimrichter L; Guimarães AJ
Front Cell Infect Microbiol; 2020; 10():565571. PubMed ID: 33585262
[TBL] [Abstract][Full Text] [Related]
59. The cellular responses induced by the capsular polysaccharide of Cryptococcus neoformans differ depending on the presence or absence of specific protective antibodies.
Vecchiarelli A
Curr Mol Med; 2005 Jun; 5(4):413-20. PubMed ID: 15977997
[TBL] [Abstract][Full Text] [Related]
60. Glucuronoxylomannan exhibits potent immunosuppressive properties.
Monari C; Bistoni F; Vecchiarelli A
FEMS Yeast Res; 2006 Jun; 6(4):537-42. PubMed ID: 16696649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
